Anuh Pharma Board Meet May 20, 2026: Results, Dividend

Board meeting date and key agenda items

Anuh Pharma Ltd has scheduled a meeting of its Board of Directors for May 20, 2026. The core agenda includes consideration and approval of the audited financial results for the fourth quarter and the financial year ended March 31, 2026. Alongside the results, the board is also set to take up the question of a dividend for the financial year ended March 31, 2026. The company has also indicated that director-related items will be part of the same meeting. Such board meetings are closely tracked because audited annual results typically carry the most complete view of performance, including audit observations, if any. Dividend recommendations, when made, also become a key corporate action for shareholders to monitor. The intimation also carries trading window compliance updates for designated persons.

Audited Q4 and FY26 results to be considered

The May 20, 2026 meeting is meant to consider and approve audited financial results for Q4 and the year ended March 31, 2026. The term “audited” is important because it indicates the results will be accompanied by the statutory audit process for the full year. The company has not provided any FY26 numbers in the information shared here, but the agenda confirms that the board discussion will cover both quarter and full-year financial statements. Investors typically watch for revenue, profit, cash flows, and notes to accounts, especially around changes in costs, working capital, and any exceptional items. The meeting outcome, once disclosed, is expected to clarify the audited results status for FY2025-26. Any approval is generally followed by exchange filings that carry detailed statements and audit reports.

Dividend for FY ended March 31, 2026 on the table

Anuh Pharma’s board will also consider a dividend for the financial year ended March 31, 2026. At this stage, only the “consideration of dividend” is known, and no dividend amount has been stated. If the board recommends a dividend, it is typically subject to shareholder approval at the company’s Annual General Meeting, depending on applicable requirements and the company’s own processes. The dividend decision generally draws attention because it signals management’s stance on cash distribution versus reinvestment. Investors will also track record dates, ex-dates, and payment timelines once the company announces them.

Director re-appointments proposed

The agenda includes re-appointment of directors Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal. Re-appointments are standard corporate governance items that can be routed through board and shareholder approvals, depending on the director category and tenure. The disclosure confirms these two names are part of the May 20, 2026 meeting agenda, but it does not specify the role types, term length, or committee positions. Investors generally monitor such items as part of governance continuity and board composition. The detailed terms, if any, would normally be available in subsequent filings or AGM notice materials.

Trading window closure: April 1 to May 22, 2026

The company has stated that the trading window is closed from April 1 to May 22, 2026 for designated persons. Trading window closures are typically applied under insider trading regulations to restrict trading when unpublished price sensitive information, such as financial results, is being prepared and reviewed. The closure period extends beyond the board meeting date, suggesting the window will reopen after the results-related compliance process is completed. For investors, this is largely a process disclosure, but it also confirms the timeline around the audited results cycle. Companies often reiterate such closure windows around quarterly and annual results announcements.

What earlier disclosures show about results cadence

The information set also references prior board meeting intimations related to unaudited financial results for earlier periods. A board meeting was scheduled for February 6, 2026 to review and approve unaudited financial results for Q3 ended December 31, 2025, along with a trading window closure from January 1, 2026 to February 8, 2026. Separately, the company had disclosures around unaudited financial results for the quarter and half year ended September 30, 2025, including newspaper publication dated November 9, 2025 in Financial Express (English) and Mumbai Lakshdeep (Marathi). These references help establish the pattern of periodic results approvals and related compliance steps. They also indicate the company uses standard exchange and publication routes for results dissemination.

Snapshot: recent market and corporate action references

The provided information includes certain market and corporate action references for Anuh Pharma. The stock was noted as down 1.19% from a previous close of Rs 77.56, with a last traded price of Rs 76.64. A dividend yield of 1.96% is also mentioned in the same context. On corporate actions, the data points include a dividend of Rs 1.50 per share with an ex-date of August 14, 2025, and a bonus issue in the ratio 1:1 with an ex-date of July 15, 2025. These items are historical references in the supplied material and are separate from the FY2025-26 dividend consideration now scheduled for May 20, 2026.

Historical financial data points mentioned (converted to INR crore)

While the May 2026 meeting is about FY2025-26 audited results, the material includes a small table of earlier financial results stated in lakhs. Converting these to INR crore (1 crore = 100 lakhs) provides consistent scale.

The material also notes total assets as of March 31, 2025 at INR 506.63 crore. These figures relate to previously reported periods and do not indicate FY2025-26 performance by themselves.

Key dates and disclosures at a glance

The following table consolidates the dated items mentioned in the supplied information.

Market impact: what investors will track next

The immediate market relevance is tied to the release of audited Q4 and full-year FY2025-26 numbers after the May 20, 2026 board meeting. Investors will watch for the audited income statement and profit trends, the audit report status, and any notes that materially affect comparability with earlier periods. The dividend agenda item adds another point of focus, particularly if the company announces a recommendation, record date, and shareholder approval pathway. The director re-appointment items are governance-related and can matter for board stability and continuity. Separately, the trading window closure provides a clear compliance timeline that may affect insider participation, but it does not change public market trading for regular shareholders.

Analysis: why the May 20, 2026 meeting matters

This board meeting combines three high-signal items: audited annual results, a dividend consideration, and board composition actions. Audited full-year results generally carry more weight than unaudited quarterly numbers because they reflect year-end provisions, audit adjustments, and full disclosures. Dividend consideration can influence investor expectations on cash return, especially when viewed alongside past corporate actions referenced in the same information set. Re-appointment of directors is a routine item but remains important because it shapes continuity in oversight. The market will likely remain focused on the detailed filings that follow the board decision, since the agenda alone does not disclose financial outcomes.

Conclusion

Anuh Pharma’s May 20, 2026 board meeting is set to address audited Q4 and FY2025-26 results, a possible dividend for the year ended March 31, 2026, and the re-appointment of two directors. The trading window remains closed for designated persons from April 1 to May 22, 2026. The next concrete update for investors will come from the company’s post-meeting exchange disclosures, which should carry the audited results and any dividend recommendation details, if approved.